Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab′)2 fragment derived from equine polyclonal antibodies-Reference-Cited by-同舟云学术

Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab′)2 fragment derived from equine polyclonal antibodies

Published:2022-01 Issue: Volume:434 Page:115796
ISSN:0041-008X
Container-title:Toxicology and Applied Pharmacology
language:en
Short-container-title:Toxicology and Applied Pharmacology

Author:

Salinas Facundo,Marelli Belkis E.,Sanguineti Santiago,Goldbaum Fernando,Muñoz Luciana,Etchevers Lucas,Silvestrini Paula,Notaro Ulises S.,Salvetti Natalia R.,Zylberman Vanesa,Ortega Hugo H.

Publisher

Elsevier BV

Subject

Pharmacology,Toxicology

Reference51 articles.

1. A serological assay to detect SARS-CoV-2 seroconversion in humans;Amanat;Nat. Med.,2020

2. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses;Artese;Drug Resist. Updat.,2020

3. Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab′)2 fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study;Bal;Lancet Infect. Dis.,2015

4. An overview of some potential immunotherapeutic options against COVID-19;Bayat;Int. Immunopharmacol.,2021

5. Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology;Berry;New Biotechnol.,2011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab′)2 fragments;Scientific Reports;2023-08-25

2. SARS CoV-2 infections in animals, two years into the pandemic;Archives of Virology;2022-10-07

3. Development and Validation of an ELISA to Evaluate Neutralizing Equine Anti Shiga Toxin Antibodies in Preclinical Studies;Venoms and Toxins;2022-08